GlassScriptPhysician profile
Kimberly A Smith
NPI 1407492531
$8,964.99
in general payments reported to CMS, 2019-2025
32 companies · $2,221 in 2025
The $2,221 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,797 · 2022: $1,852 · 2023: $1,348 · 2024: $1,746 · 2025: $2,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,315.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,509.94 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,418.07 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $1,245.84 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $737.20 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $650.92 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $451.68 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $358.01 | 2021-2025 | Rexulti, Brintellix |
| Sunovion Pharmaceuticals INC. | $348.59 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $324.68 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $308.00 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $240.63 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $198.15 | 2021-2025 | Spravato, Invega Sustenna |
| Indivior INC. | $179.72 | 2021-2024 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $133.33 | 2021-2022 | |
| Corium, LLC | $120.09 | 2022-2024 | Azstarys |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $92.93 | 2024-2025 | Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $83.47 | 2021-2024 | Qelbree |
| Uswm, LLC | $80.87 | 2021 | |
| Bausch Health US, LLC | $78.42 | 2021-2023 | Aplenzin |
| Tempus Ai, INC | $66.78 | 2024 | |
| Merck Sharp & Dohme LLC | $38.73 | 2022 | |
| Sage Therapeutics, LLC | $37.79 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $37.02 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $32.10 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $31.24 | 2022 | |
| Eisai INC. | $28.35 | 2021 | |
| Almatica Pharma LLC | $28.33 | 2024 | Loreev Xr |
| Nevro Corp. | $28.00 | 2024 | Senza |
| Bioventus LLC | $22.46 | 2023 | Durolane |
| Braeburn INC. | $20.77 | 2025 | Brixadi |
| Ironshore Pharmaceuticals INC. | $17.02 | 2023 | Jornay Pm |
| Noven Therapeutics, LLC | $15.86 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.